NYMC Faculty Publications
First Page
27
Last Page
27
Document Type
Article
Publication Date
7-4-2016
Department
Medicine
Second Department
Neurosurgery
Abstract
Ibrutinib is a novel targeted therapy for B-cell malignancies. Hemorrhagic events were reported in the original trials, however the mechanism of bleeding is just being elucidated. Recent studies have demonstrated platelet dysfunction as a mechanism of bleeding. Currently we report two patients who developed life-threatening central nervous system hemorrhage while receiving ibrutinib for chronic lymphoid leukemia (CLL) and mantle cell lymphoma, respectively. Both patients improved rapidly after platelet transfusions even though their platelet counts were normal or only mildly reduced at the time of hemorrhage. We suggest that platelet transfusions can ameliorate the platelet dysfunction defect of ibrutinib and can support the patient through the critical period until new platelet production occurs.
Recommended Citation
Seiter, K., Stiefel, M. F., Barrientos, J., Shaikh, A., Ahmed, N., Baskind, P., & Liu, D. (2016). Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. Stem Cell Investigation, 3, 27. doi:10.21037/sci.2016.06.08
Publisher's Statement
Originally published in Stem Cell Investigation. Licensed under CC-BY 4.0. https://doi.org/10.21037/sci.2016.06.08
Comments
Please see the work itself for the complete list of authors.